Induction-maintenance intravesical gemcitabine after transurethral resection for intermediate- and selected high-risk non-muscle-invasive bladder cancer: A propensity score-matched cohort study

Background: Conventional intravesical chemotherapeutic agents for non-muscle-invasive bladder cancer (NMIBC) are limited by drug resistance and local adverse reactions, which may restrict their clinical benefit. Objectives: This study aimed to evaluate the clinical efficacy, urinary and serum concentration indicators, safety and exploratory pharmacoeconomic value of induction-maintenance intravesical gemcitabine as postoperative adjuvant therapy for intermediate- and selected high-risk NMIBC. Methods: A retrospective propensity score-matched cohort design was used. A total of 294 patients with intermediate- and selected high-risk NMIBC who underwent transurethral resection of bladder tumor from January 2022 to October 2023 were screened and follow-up records were reviewed through 31 October 2025. After 1:1 nearest-neighbor matching, 100 patients were retained in the induction-maintenance intravesical gemcitabine group and 100 in the conventional intravesical mitomycin group; tumor recurrence, recurrence-free survival, urinary and serum concentration indicators, adverse events and direct medical costs were compared between the two groups. Results: The tumor recurrence rates at 12 and 24 months were lower in the gemcitabine group than in the mitomycin group (p=0.008) and the mean recurrence-free survival time was longer in the gemcitabine group (p<0.001). The overall incidence of adverse events was lower in the gemcitabine group than in the mitomycin group (p=0.011) and the completion rate of the instillation course was higher in the gemcitabine group (p=0.038). The gemcitabine group showed lower 24-month direct medical costs and higher QALYs, indicating a dominant cost-saving pattern in this exploratory economic analysis. Conclusion: Induction-maintenance intravesical gemcitabine was associated with lower recurrence and better treatment completion than mitomycin in this matched cohort, but the study was not designed to compare gemcitabine with Bacillus Calmette-Guérin and should not be interpreted as establishing superiority or non-inferiority to BCG in high-risk NMIBC.

Authors

Publication Details

Journal
Pakistan Journal of Pharmaceutical Sciences
Published
2026-11-19
DOI
https://doi.org/10.36721/pjps/2026.40.16893.1
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Induction-maintenance intravesical gemcitabine after transurethral resection for intermediate- and selected high-risk non-muscle-invasive bladder cancer: A propensity score-matched cohort study

Junqing Gu
Pakistan Journal of Pharmaceutical Sciences
Bladder and Urothelial Cancer Treatments
article

Induction-maintenance intravesical gemcitabine after transurethral resection for intermediate- and selected high-risk non-muscle-invasive bladder cancer: A propensity score-matched cohort study

Junqing Gu
article en

Abstract

Background: Conventional intravesical chemotherapeutic agents for non-muscle-invasive bladder cancer (NMIBC) are limited by drug resistance and local adverse reactions, which may restrict their clinical benefit. Objectives: This study aimed to evaluate the clinical efficacy, urinary and serum concentration indicators, safety and exploratory pharmacoeconomic value of induction-maintenance intravesical gemcitabine as postoperative adjuvant therapy for intermediate- and selected high-risk NMIBC. Methods: A retrospective propensity score-matched cohort design was used. A total of 294 patients with intermediate- and selected high-risk NMIBC who underwent transurethral resection of bladder tumor from January 2022 to October 2023 were screened and follow-up records were reviewed through 31 October 2025. After 1:1 nearest-neighbor matching, 100 patients were retained in the induction-maintenance intravesical gemcitabine group and 100 in the conventional intravesical mitomycin group; tumor recurrence, recurrence-free survival, urinary and serum concentration indicators, adverse events and direct medical costs were compared between the two groups. Results: The tumor recurrence rates at 12 and 24 months were lower in the gemcitabine group than in the mitomycin group (p=0.008) and the mean recurrence-free survival time was longer in the gemcitabine group (p<0.001). The overall incidence of adverse events was lower in the gemcitabine group than in the mitomycin group (p=0.011) and the completion rate of the instillation course was higher in the gemcitabine group (p=0.038). The gemcitabine group showed lower 24-month direct medical costs and higher QALYs, indicating a dominant cost-saving pattern in this exploratory economic analysis. Conclusion: Induction-maintenance intravesical gemcitabine was associated with lower recurrence and better treatment completion than mitomycin in this matched cohort, but the study was not designed to compare gemcitabine with Bacillus Calmette-Guérin and should not be interpreted as establishing superiority or non-inferiority to BCG in high-risk NMIBC.

Pakistan Journal of Pharmaceutical Sciences
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon